Indivior settles Suboxone lawsuits with Mylan

Indivior has struck an out-of-court settlement to resolve litigation over its Suboxone opiate addiction treatment with Mylan Pharmaceuticals.

The UK company had filed the litigation after Mylan's submitted a new drug application to the US Food & Drug Administration seeking approval to market generic versions of Indivior's Suboxone film.

The terms of the settlement are confidential, Indivior said, and will be submitted to the US Federal Trade Commission and Department of Justice for review.

"We are pleased to have amicably settled all outstanding litigation with Mylan," said chief executive Shaun Thaxter.

"The agreement at once reflects our desire to create further certainty for Indivior and underscores the strength of our intellectual property.

"Further, as recently demonstrated with our newly granted '454 patent, we expect to expand the intellectual property estate for Suboxone Film and vigorously assert and defend it."

As well as against Mylan, earlier this month, the company filed lawsuits against generic drug makers Dr Reddy's, Actavis, Par, Alvogen and Teva, following other patent infringement litigation over earlier issued Suboxone patents with these same companies.

Indivior is also still preparing to launch an appeal after a court ruled against an older patent, meaning generic versions of Suboxone may soon sold in the US once they gain approval from the FDA.